Core Viewpoint - Genting New Year (01952) has seen a stock price increase of over 4%, currently trading at 45.8 HKD, with a transaction volume of 172 million HKD, following the announcement of two strategic cooperation agreements with Haisen Biopharmaceutical [1] Group 1: Strategic Agreements - Genting New Year’s wholly-owned subsidiary, Genting New Year Pharmaceutical Technology, has signed two strategic cooperation agreements with Haisen Biopharmaceutical [1] - Under the commercialization service agreement, Genting New Year Pharmaceutical Technology will leverage its existing sales and marketing system to provide commercialization services for six mature products from Haisen Biopharmaceutical, focusing on critical care, cardiovascular, and metabolic fields [1] Group 2: Licensing Agreement - The licensing agreement grants Genting New Year Pharmaceutical Technology exclusive rights to conduct further clinical development, registration, and commercialization of Lerodalcibep in Greater China, enhancing its late-stage pipeline [1] - According to the licensing agreement, Genting New Year Pharmaceutical Technology will make an initial payment of approximately 205 million CNY, with potential development and regulatory milestone payments not exceeding 212 million CNY, and potential sales milestone payments not exceeding 1.977 billion CNY, along with potential royalties based on net sales [1]

Group 1 - The core viewpoint of the news is that CloudTop New Horizon has signed two strategic cooperation agreements with Haisen Biopharmaceutical, which will enhance operational efficiency and commercial capabilities in the cardiovascular disease sector [1][2] - The commercialization service agreement allows CloudTop New Horizon to provide services for six mature products from Haisen Biopharmaceutical, with service fees ranging from 20% to 55% of the quarterly net sales [1] - The annual transaction caps for Haisen Biopharmaceutical are set at RMB 560 million for 2026, RMB 616 million for 2027, and RMB 677 million for 2028 [1] Group 2 - The licensing agreement grants CloudTop New Horizon exclusive rights to develop, register, and commercialize Lerodalcibep in Greater China, enhancing its late-stage pipeline [2] - An initial payment of approximately RMB 205 million will be made by CloudTop New Horizon, along with potential milestone payments totaling up to RMB 2.12 billion for development and regulatory milestones, and up to RMB 19.77 billion for sales milestones [2] - Lerodalcibep is a third-generation PCSK9 inhibitor developed by LIB Therapeutics, aimed at lowering LDL-C levels in patients with high cholesterol [2]

Group 1: Industry Developments - Jiangsu Province has officially released its 15th Five-Year Plan, emphasizing the enhancement of industries such as biomedicine, new generation information technology, and high-end equipment, aiming to cultivate strategic emerging industry clusters with international competitiveness [1] - The global first CDK2/4/6 inhibitor, Kimosir, developed by China National Pharmaceutical Group's subsidiary, has been approved for marketing, marking a significant advancement in targeted therapy for breast cancer in China [1] - The innovative drug, Simoziran, developed by Shanghai Pharmaceuticals, has been approved for the treatment of primary hypertension, representing a new addition to the hypertension treatment market [2] Group 2: Company Announcements - Health元 has received a drug registration certificate for its innovative anti-influenza drug, Marpacisavir, which is effective for treating influenza A and B in adolescents and adults, showcasing significant advantages in efficacy and safety [3] - Baijun Medical's subsidiary has received approval for its collagen implant product, the first of its kind in China for improving facial smoothness, highlighting the company's innovation in the collagen field [4] - Innovent Biologics has announced the approval of its next-generation TRK inhibitor, Zoltritinib, for treating adult and adolescent patients with NTRK fusion gene solid tumors, marking a milestone in China's oncology market [5] Group 3: Market Movements - Saili Medical has reported a reduction in shareholding by Shanghai Anze Private Equity Fund to 5.00%, indicating a strategic shift in investment [6][7] - Newnow has submitted an application for H-share listing on the Hong Kong Stock Exchange, reflecting the trend of innovative pharmaceutical companies seeking dual listings [8] - Yunding New Medicine has entered into strategic cooperation with Haishen Biopharmaceuticals, enhancing its commercialization capabilities in the cardiovascular field through service and licensing agreements [9]

Core Insights - Cloudtop New Horizon (HKEX 1952.HK) has signed two strategic cooperation agreements with Haisen Biopharmaceutical Co., Ltd., which will enhance operational efficiency and commercial capabilities in the cardiovascular disease sector [1][3] Group 1: Strategic Agreements - The commercial service agreement allows Cloudtop New Horizon to leverage its existing sales and marketing system to provide commercialization services for six mature products from Haisen Biopharmaceutical, focusing on critical care, cardiovascular, and metabolic fields [1] - The licensing agreement grants Cloudtop New Horizon exclusive rights for the clinical development, registration, and commercialization of Lerodalcibep in Greater China, enriching its late-stage pipeline [1] Group 2: Financial Terms - Under the licensing agreement, Cloudtop New Horizon will make an initial payment of approximately 205 million yuan, with potential milestone payments not exceeding 212 million yuan for development and regulatory milestones, and up to 1.977 billion yuan for sales milestones, along with potential royalties based on net sales [1] Group 3: Product Overview - Lerodalcibep, developed by LIB Therapeutics, is a third-generation PCSK9 inhibitor designed to lower LDL-C levels in patients with high cholesterol, including heterozygous familial hypercholesterolemia [2] - The product is designed for convenient monthly subcutaneous injection and has shown significant efficacy in clinical trials, with applications submitted to the FDA and EMA, and a BLA submission expected in mid-2026 in Greater China [2] Group 4: Industry Implications - This collaboration is seen as a critical step in strengthening Cloudtop New Horizon's full industry chain layout, aligning with its long-term development strategy and enhancing its core competitiveness [3]